Q-Line Biotech Limited

Q-Line Biotech (NEW IPO) :GMP, Profit, Price & expert review

by

Q-Line Biotech Limited is a prominent player in the Indian In-Vitro Diagnostic (IVD) industry, specializing in the manufacturing and distribution of biochemistry reagents, hematology analyzers, and rapid diagnostic kits. Originally known as POCT Services, the company rebranded to align with its flagship “Q-Line” brand and now operates with ISO 9001:2015 certification, serving over 15,000 customers globally.

Q-Line Biotech Limited was incorporated on November 10, 2010 & the company is currently led by Mr. Saurabh Garg.

Q-Line Biotech Limited provides comprehensive In-Vitro Diagnostic (IVD) solutions, including biochemistry reagents, hematology analyzers, and molecular diagnostic kits. Their portfolio features rapid test cards, ELISA kits, and advanced pathology equipment like automated urine chemistry and electrolyte analyzers, catering to hospitals and laboratories globally. Q-Line operates through a massive distribution network of 150+ distributors, reaching over 15,000 customers across India.

Q-Line Biotech Limited has filed DRHP for upcoming IPO consisting entirely as a Fresh Issue of 7,053,200 Equity Shares and no Offer for Sale.

Subscription date to apply for Q-Line Biotech Limited is yet to be announced. Price band for the IPO is yet to be declared.

Check DRHP
Check IPO Allotment
Visit Official Website
Issue Size:70,53,200 Equity Shares
Fresh Issue:70,53,200 Equity Shares
Offer for Sale:N/A
Price Range:TBA
Lot Size:TBA
GMPPending

Q-Line Biotech Limited important data points

Revenue, PAT, EBITDA

YearFiscal 2025
Networth₹ 189.94 Cr
Revenue:₹ 313.78 Cr
EBITDA₹ 71.32 Cr
EBITDA Margin:22.23%
PAT₹ 28.13 Cr
PAT Margin8.97%
Face Value:₹ 10

IPO important dates

Open Date:TBA
Close Date:TBA
Anchor Investor BiddingTBA
Allotment Date:TBA
Refunds & Demat CreditTBA
Tentative Listing Date:TBA

Use of Proceeds

PurposeAmount
Borrowing Repayment/Pre-payment~ ₹ 90.00 Cr
Working Capital Requirements~ ₹ 110 Cr
Sales and Marketing~ ₹ 00 Cr
Ultra-Advanced AI Staffing Suite₹ 00 Cr

Q-Line Biotech Limited Financial Data

202320242025
Revenue (₹ Cr)₹ 182.7₹ 203.6₹ 313.8
PAT (₹ Cr)₹ 32.1₹ 34.4₹ 28.1
Asset (₹ Cr)₹ 176.1₹ 198.5₹ 264.6
Net Worth (₹ Cr)₹ 127.4₹ 161.8₹ 189.9

Q-Line Biotech Limited IPO Grey Market Premium

DateIPO PriceIPO GMPProfit per lot
05-Apr₹ –₹ –₹ –
04-Apr₹ –₹ –₹ –
03-Apr₹ –₹ –₹ –
02-Apr₹ –₹ –₹ –
01-Apr₹ –₹ –₹ –
Q-Line Biotech Limited

Q-Line Biotech Limited IPO Pros & Cons

Strengths:

  • Strong Financial Growth: Reported a healthy CAGR of approximately 21% in revenue over the last four years.
  • Diversified Revenue Streams: Generates income from reagents, diagnostic equipment, and laboratory services, reducing single-product dependency risks.
  • Widespread Distribution Network: Operates an extensive network of 150+ distributors providing a strong nationwide presence across India.
  • In-House R&D Focus: Strong emphasis on indigenous manufacturing and reverse engineering, supporting the “Make in India” initiative.
  • Healthy Profitability Margins: Maintains stable operating margins of over 20%, reflecting efficient production and cost management.

Risks:

  • High Working Capital: Operations are capital-intensive with high inventory and receivable days, potentially straining future liquidity.
  • Intense Market Competition: Faces stiff pricing pressure from both established global giants and numerous local diagnostic players.
  • SME Listing Volatility: Proposed listing on the NSE SME platform typically involves lower liquidity and higher volatility.
  • Customer Concentration Risk: Significant revenue depends on long-term contracts with government hospitals and large diagnostic centers.
  • Regulatory Compliance Burden: Expansion into 15+ countries requires constant, costly adherence to evolving international healthcare regulations.

Q-Line Biotech Limited Promoters – Pre offer equity (Approx)

Promoters%Shares
Saurabh Garg62.62%
Amita Garg24.19%
Abhay Agrawal4.65%
Ajay Kumar Mahanty4.61%
Ayush Garg0.19%

Q-Line Biotech Limited Lot Size details

Application TypeLot SizeNo. of LotNo. of SharesInvestment Amount
Retail (Min)–1–₹ –
Retail (Max)–13–₹ –
HNI (Min)–14–₹ –
HNI (Max)–66–₹ –
Big HNI (Min)–67–₹ –

Lead Managers / Registrars of Q-Line Biotech Limited

Lead / Book Running Lead ManagersSHARE INDIA CAPITAL SERVICES PRIVATE LIMITED, HEM SECURITIES LIMITED 
Registrar (RTA)PURVA SHAREGISTRY
(INDIA) PRIVATE LIMITED

FAQ’s of Q-Line Biotech Limited

  • It manufactures and distributes In-Vitro Diagnostic (IVD) medical devices, biochemistry reagents, and advanced laboratory equipment globally.

  • Q-Line Biotech Limited is raising funds via IPO to fulfill working capital requirements, repay existing borrowings, and support general corporate purposes.

  • The issue size of the IPO comprises 7,053,200 equity shares. It will be listed on the NSE Emerge platform.

  • Key risks include high working capital intensity, dependence on third-party distributors, and potential regulatory non-compliance or manufacturing shutdowns.

  • Potential upsides include strong revenue growth (21% CAGR), a diversified IVD product portfolio, and a robust pan-India distribution network.

  • You can apply for the IPO via ASBA through bank net banking, UPI on trading apps, or through your broker once the IPO opens for subscription.

  • Toggle Content

For more amazing blogs click here (IPO Corner).

Leave a comment